X4 Pharmaceuticals, Inc. (XFOR) NASDAQ
4.23
-0.11(-2.53%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.23
-0.11(-2.53%)
Currency In USD
Address
61 North Beacon Street
Boston, MA 02134
United States of America (the)
Phone
857 529 8300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
November 16, 2017
| Name | Title | Pay | Year Born |
| John Volpone | President & Chief Operating Officer | 532,988 | 1975 |
| Adam R. Craig | Executive Chair | 575,546 | 1966 |
| David H. Kirske | Chief Financial Officer, Treasurer & Corporate Secretary | 722,331 | 1954 |
| Keith T. Flaherty | Founder & Member of Corporate Advisory Board | 0 | 1971 |
| Renato T. Skerlj | Founder | 0 | N/A |
| Richard Peters | Founder | 0 | 1962 |
| Brian Bowersox | Vice President of Finance & Corporate Controller | 0 | N/A |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.